Guangzhou Magpie Pharmaceuticals Co., Ltd.
Wednesday, June 05, 2024
CNS/Neurological
Company Presentation Theater 4
Guangzhou Magpie Pharmaceuticals Co., Ltd. (MPI) is a leading biotech company in Guangzhou, China with a robust pipeline of late-stage clinical assets. MPI focuses on developing novel treatments for cerebro-cardiovascular, neurodegenerative, and mitochondrial dysfunction diseases, as well as diabetic kidney disease. Currently MPI has 7 new NCEs in development: 3 phase III, 6 phase II, and 1 phase I clinical stage assets in China; and 2 phase I-ready assets in the US.
Company Website:
https://www.magpiepharma.com/
Lead Product in Development:
TBN, MN-08
Company HQ City
Guangzhou
Company HQ State
Guangdong Province
Company HQ Country
China
CEO/Top Company Official
Yuqiang Wang
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())